Period:
Draw Mode:
| Volume | 1,263 |
|
|||||
| News | - | ||||||
| Day High | 3.14 | Low High |
|||||
| Day Low | 2.94 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Oragenics Inc | OGEN | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.1999 | 6.8% | 3.1399 | 12:27:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.94 | 2.94 | 3.14 | 2.94 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 54 | 1,263 | $ 3.14 | $ 3,962 | - | 2.58 - 17.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:29:10 | 8 | $ 2.94 | USD |
Oragenics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 7.97M | - | - | - | -261.38 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oragenics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OGEN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.89 | 3.2265 | 2.75 | 2.88 | 4,354 | 0.2499 | 8.65% |
| 1 Month | 3.63 | 3.635 | 2.75 | 3.13 | 5,526 | -0.4901 | -13.5% |
| 3 Months | 3.33 | 4.48 | 2.65 | 3.53 | 10,616 | -0.1901 | -5.71% |
| 6 Months | 3.07 | 4.48 | 2.58 | 3.34 | 10,213 | 0.0699 | 2.28% |
| 1 Year | 14.298 | 17.40 | 2.58 | 9.32 | 238,943 | -11.16 | -78.04% |
| 3 Years | 33.03 | 108.00 | 2.58 | 48.40 | 3,870,836 | -29.89 | -90.49% |
| 5 Years | 83.40 | 224.40 | 2.58 | 55.19 | 3,504,870 | -80.26 | -96.24% |
Oragenics Description
| Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. |